Supernus Pharmaceuticals 株価情報 (NASDAQ: SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN) 株価情報

Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals Inc

Cantor Fitzgerald analyst Kristen Kluska reiterates Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) with a Neutral and maintains $36 price target.

News

Price Target

Reiteration

Analyst Ratings

SUPN

Cantor Fitzgerald Reiterates Neutral on Supernus Pharmaceuticals, Maintains $36 Price Target

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) sees FY2025 sales of $600.000 million-$630.000 million vs $622.18 million analyst estimate.

Guidance

Supernus Pharmaceuticals Sees FY2025 Sales $600.000M-$630.000M vs $622.18M Est

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.52 by 48.08 percent. This is a 30.77 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $174.16 million which beat the analyst consensus estimate of $155.25 million by 12.18 percent. This is a 5.99 percent increase over sales of $164.31 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Supernus Pharmaceuticals Q4 EPS $0.27 Misses $0.52 Estimate, Sales $174.16M Beat $155.25M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowered the price target from $52 to $42. Qiagen shares closed at $40.01 on Tuesday. <a href="https://www.benzinga.com/quote/QGEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Catherine Schulte downgraded Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Outperform to Neutral and lowered the price target from $88 to $68. Bio-Techne shares closed at $65.29 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss downgraded Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Overweight to Equal-Weight and lowered the price target from $330 to $275. Workday shares closed at $265.72 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Kyle Bauser downgraded the rating for Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral and slashed the price target from $23 to $18. Tactile Systems shares closed at $17.86 on Tuesday. <a href="https://www.benzinga.com/quote/TCMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Kristen Kluska downgraded Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowered the price target from $57 to $36. Supernus Pharmaceuticals shares closed at $39.75 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="427" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png" alt="" class="wp-image-788949" style="width:460px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-300x125.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-768x320.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

CRVO

QGEN

TCMD

TECH

WDAY

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

On Tuesday, Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) revealed the topline data from the Phase 2b study of SPN-820 in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43798052/supernus-announces-topline-results-from-phase-2b-study-in-adults-with-treatment-resistant-depressi" rel="noreferrer noopener">treatment-resistant depression (TRD)</a>.
The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score to Week 4, a widely used clinician‐rated measure of depressive severity.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40820529/adhd-drug-maker-supernus-pharmaceuticals-downgraded-on-slower-prescription-growth-f" rel="noreferrer noopener">ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug</a>
There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints.
The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events.
&#8220;We are disappointed that the trial did not meet its primary endpoint in this patient population,&#8221; said Jack Khattar, President and CEO of Supernus. &#8220;We will continue to analyze these data and discuss the future of the program with our development partner, Navitor Pharmaceuticals.&#8221;
In October, Supernus Pharmaceuticals revealed data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41390811/supernus-announces-promising-data-from-open-label-phase-2a-study-of-spn-820-in-adults-with-major-d" rel="noreferrer noopener">major depressive disorder</a>.
Phase 2a study demonstrated a rapid and substantial decrease in depressive symptoms. SPN-820 was well-tolerated with few adverse events.
Earlier this month, the FDA approved&nbsp;Supernus Pharmaceuticals&#8217; ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43462326/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinsons-disease" rel="noreferrer noopener">advanced Parkinson&#8217;s disease</a>.
Supernus will make ONAPGO available in the second quarter of 2025.
Price Action: SUPN stock is down 14.10% at $34.20 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/02/43811409/nikola-files-for-bankruptcy-seeks-auction-for-sale-of-its-assets" target="_blank" rel="noreferrer noopener">Nikola Files For Bankruptcy, Seeks Auction For Sale Of Its Assets</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

WIIM

Supernus Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral and cut its price target from $57 to $36.

Cantor Fitzgerald analyst Kristen Kluska downgrades Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowers the price target from $57 to $36.

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral, Lowers Price Target to $36

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday.
Shares of Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/THRM/news">weak quarterly results.</a>
Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) fell 14.7% to $6.40 in pre-market trading after jumping 153% on Tuesday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 11.9% to $24.94 in pre-market trading following weak quarterly results.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) fell 7.7% to $3.60 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) declined 6.8% to $53.35 in pre-market trading after reporting a 6.8% YoY decline in fourth-quarter GMV and guiding for a similar YoY GMV decline in the first quarter.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) fell 5.4% to $115.50 in pre-market trading after the company reported worse-than-expected first-quarter financial results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

BMBL

ETSY

INNV

SLSR

THRM

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for <a href="https://www.benzinga.com/quote/gb/analyst-ratings">$7.50 per share</a>.
Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) rose 132.5% to $7.79 in pre-market trading after dipping 72% on Tuesday.</li>
<li>OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares jumped 96.4% to $6.11 in pre-market trading after gaining 3% on Tuesday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 52.7% to $0.34 in pre-market trading after dipping 14% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 43.3% to $1.55 in pre-market trading. ReShape Lifesciences shares dipped around 54% on Tuesday after the company announced a $6 million public offering of 2,575,107 units at $2.33 per unit.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares climbed 38.3% to $3.90 in pre-market trading. Sintx Technologies announced the issuance of U.S. patent no. 12,239,761 by the United States Patent and Trademark Office.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) gained 35.2% to $2.96 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 33.1% to $0.5444 in pre-market trading after the company guided 2024 sales of $22.5 million and 2H adjusted EBITDA above $2.2 million.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 22.3% to $0.1345 in pre-market after surging 57% on Tuesday.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) rose 14.5% to $8.00. MFH&#8217;s majority-owned subsidiary Aifinity Base Limited plans to manufacture advanced liquid cooling solutions for Nvidia&#xAE; chip-powered AI data centers and high-performance computing.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares fell 36.4% to $3.25 in pre-market trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 25.5% to $0.1439 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Design Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 24.5% to $3.120 in pre-market trading.</li>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 20.9% to $0.3680 in pre-market trading after dipping 35% on Tuesday. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell 17% to $30.00 in pre-market trading following weak quarterly results.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 10.6% to $4.60 in pre-market trading following a 7% decline on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

ADTX

APTO

CYCU

DSGN

MGOL

MOVE

NEXA

NIVF

OSRH

RSLS

SINT

TRUG

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.

SPN-820 was well-tolerated with few adverse events, consistent with previously reported studies.

Supernus Reports Results From Phase 2b Study In Adults With Treatment Resistant Depression; Study Did Not Show Statistically Significant Improvement On Primary Endpoint Of Reduction In Depressive Symptoms

Supernus Pharmaceuticals shares are trading higher after the company received FDA approval of ONAPGO for Parkinson's disease.

Supernus Receives FDA Approval Of ONAPGO Fr Parkinson's Disease

<ul>
<li>Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree's multimodal pharmacodynamics &nbsp;</li>
<li>Qelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies1 &nbsp;</li>
</ul>
ROCKVILLE, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an update for the label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data in Section 12.2. The updated label describes viloxazine's partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, reinforcing its multimodal pharmacodynamic profile. The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Additionally, the updated label now includes new lactation data for breastfeeding women with attention-deficit/hyperactivity disorder (ADHD), showing that the transfer of Qelbree into breastmilk is low. Qelbree is approved for use in patients ages 6 years and older with ADHD.

Supernus Pharmaceuticals Announces FDA Approval Of Updated Qelbree Label With New Data On Serotonin 5-HT2C Partial Agonist Activity, Norepinephrine Transporter Inhibition, And Low Transfer In Breastmilk

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="583" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-1024x583.jpg" alt="" class="wp-image-3701" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-1024x583.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-300x171.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-768x437.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Screening For Bargains On Black Friday</h2>
Since American retailers traditionally offer deals on the day after Thanksgiving (&#8220;Black Friday&#8221;), it seemed fitting to see if the stock market was offering any too. The main metric I used to screen for deals was Chartmill&#8217;s overall valuation rating. I used that, because it incorporates several measures of valuation, including Price/Earnings (P/E), Forward P/E, Price/Book, and PEG (P/E divided growth rate). 
<h2 class="wp-block-heading">Setting Up The Screen&nbsp;</h2>
To make sure I wasn&#8217;t picking up a bunch of &#8220;cheap for a reason&#8221; stocks, I added a few other technical and fundamental metrics to the screen:
<ul>
<li>Trades in U.S.</li>
<li>Has options.&nbsp;</li>
<li>Valuation rating &gt;=7.&nbsp;</li>
<li>Technical rating &gt;=6</li>
<li>Set-up rating &gt;=6</li>
<li>Growth rating &gt;=6</li>
<li>Profitability rating &gt;=6</li>
<li><a href="https://www.investopedia.com/terms/p/piotroski-score.asp" target="_blank" rel="noreferrer noopener">Piotroski F-Score</a> >=8</li>
</ul>
The technical and valuation ratings are self-explanatory; the set-up rating measures the short-term consolidation of share prices. Each of those ratings is on a scale of 0 to 10, with 10 being best; the Piotroski F-Score is on a scale from 0 to 9, with 9 being best.&nbsp;
<h2 class="wp-block-heading">The Results&nbsp;</h2>
That screen yielded these four names:&nbsp;
<ul>
<li>Neurocrine Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)</li>
<li>United Therapeutics Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</li>
<li>Supernous Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>)</li>
<li>Expedia Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
</ul>
<h2 class="wp-block-heading">Are These Stocks Worth Buying Now?&nbsp;</h2>
Maybe, but they&#8217;re probably not the best stocks to buy now. The best stocks typically aren&#8217;t cheap. In <a href="https://www.zerohedge.com/news/2024-11-20/post-just-saved-us-money-nvidia" target="_blank" rel="noreferrer noopener nofollow">a recent post</a> (&#8220;The Post That Just Saved Us Money On Nvidia&#8221;), I mentioned that I&#8217;d consider placing a bullish options trade on Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) again when it had a valuation rating of 6. I didn&#8217;t say a valuation rating of 7, because as long as the AI story continues, I don&#8217;t expect Nvidia to trade that cheaply. It may not even trade at a valuation rating of 6 in the near future, outside of a major market correction. Maybe it&#8217;s not worth waiting for one. 
<h2 class="wp-block-heading">The Valuation Ratings Of Portfolio Armor&#8217;s Top Ten Names</h2>
On Wednesday, I posted Portfolio Armor&#8217;s top ten names. Those are the ones are system estimates will have the highest returns over the next six months, net of hedging costs.
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/top-names-11272024"><img loading="lazy" decoding="async" width="917" height="813" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday.jpg" alt="" class="wp-image-3702" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday-768x681.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Occasionally, we see some inexpensive stocks on that list (valuation ratings of 7 or so), but this week. The average valuation rating of the stocks in Wednesday&#8217;s top ten was 2.7. The overall top name,&nbsp;Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), had a valuation rating of 4.&nbsp;
<h2 class="wp-block-heading">The Limits Of Valuation </h2>
If you think about Tesla&#8217;s Optimus robots, you get a sense of the limitations of valuation in selecting stocks.
<figure class="wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Tesla Optimus Robot Explained" width="500" height="281" src="https://www.youtube.com/embed/1t1KMXSBrBM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The robots aren&#8217;t for sale to the general public yet, so they don&#8217;t appear in any of the metrics that comprise Tesla&#8217;s valuation rating. But Tesla CEO Elon Musk says they&#8217;ll be the most popular product in the world. If he&#8217;s right, Tesla shares will be worth a lot more in the future.&nbsp;
Deciding whether Elon is likely to be right about those robots may turn out to be a more profitable exercise for investors than crunching valuation numbers. Our system defers to the wisdom of crowds on that&#8211;the crowd of stock investors, and the crowd of options traders. Its gauges of share price movement and options sentiment suggest it makes sense to bet on Tesla now.&nbsp;
Would you like a heads up when we place our next trade based on our top names? If so, you can subscribe to our trading Substack/occasional email list below.&nbsp;
Are you are concerned about market risk? You can download our optimal hedging app by clicking on the QR code below, or aiming your iPhone camera at it.
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092919/QR-Code-8.jpg" alt="" class="wp-image-3703" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names,&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8.jpg" alt="" class="wp-image-3704" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

EXPE

NBIX

NVDA

TSLA

Screening For Black Friday Bargains In The Stock Market

Supernus Pharmaceuticals Sees FY24 Total Revenue $630M-$650M Vs $619.505M Est.

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.02 by 3350 percent. The company reported quarterly sales of $175.689 million which beat the analyst consensus estimate of $157.298 million by 11.69 percent. This is a 14.17 percent increase over sales of $153.880 million the same period last year.

Supernus Pharmaceuticals Q3 2024 GAAP EPS $0.69 Beats $0.02 Estimate, Sales $175.689M Beat $157.298M Estimate

Supernus Pharmaceuticals From A Phase 2 Study For Its SPN-820 That Shows AN 80% Decrease In Suicidal Ideation In Adults

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms
SPN-820 was well-tolerated with few adverse events
SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression
Company to host webcast today at 4:30 p.m. ET to discuss the topline data
Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025
ROCKVILLE, Md., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder. The study examined the safety and tolerability of SPN-820 2400 mg given once every 3 days as an adjunctive treatment to the current baseline antidepressant therapy, as well as assessed the rapid onset of improvement in depressive symptoms. The analysis is based on 40 enrolled subjects, of which 38 completed the 10-day treatment period.
Summary of the Data
<ul>
<li>Clinically meaningful improvement of –6.1 at two hours and –9.6 at Day 10 on the Hamilton Depression Rating Scale-6 Items (HAM-D6) total score.</li>
<li>Clinically meaningful improvement of –16.6 at four hours and –22.9 at Day 10 on the Montgomery Åsberg Depression Rating Scale (MADRS) total score.</li>
<li>Suicidal ideation decreased by 80% (12.5% with suicidal ideation at baseline decreased to 2.6% with suicidal ideation at Day 10).</li>
<li>SPN-820 was well-tolerated with few adverse events (AEs) and had acceptable tolerability with a discontinuation rate of 2.5% due to AEs.
<ul>
<li>Most common AEs related to the drug included headache, nausea, somnolence, and dizziness. Additional AEs such as cognitive disorder, dry mouth, fatigue, nasal decongestion, and paresthesia oral were observed. &nbsp;</li>
</ul>
</li>
</ul>

Supernus Reports Data From Open-Label Phase 2a Study Of SPN-820 In Adults With Major Depressive Disorder; Phase 2a Study Demonstrated Rapid And Substantial Decrease In Depressive Symptoms; SPN-820 Was Well-Tolerated With Few Adverse Events

Press Releases

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Legal

BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Comments

Supernus Pharmaceuticals

ニュース

パートナーシップ

ベンジンガ・グローバル